Proportion of female patients (aged 18 years and older) with breast cancer who are human epidermal growth factor receptor 2 (HER2)/neu negative who are not administered HER2-targeted therapies
Proportion of female patients (aged 18 years and older) with breast cancer who receive human epidermal growth factor receptor 2 (HER2) testing for overexpression or gene amplification
Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have cancer staging documented using any standardized system or documentation that the cancer is metastatic in the medical record within one month of first office visit
Patients with metastatic colorectal cancer and RAS gene mutation spared treatment with anti-epidermal growth factor receptor monoclonal antibodies
Percentage of patients who died from cancer, and admitted to hospice and spent less than 3 days there
Percentage of patients who died from cancer admitted to the ICU in the last 30 days of life
Proportion of patients who died from cancer receiving chemotherapy in the last 14 days of life
Percentage of patients who died from cancer dying in an acute care setting
Proportion of patients who died from cancer not admitted to hospice
Proportion of patients who died from cancer with more than one emergency department visit in the last 30 days of life